Core Viewpoint - Tianyi Medical (301097) experienced a decline in stock price, closing at 57.32 yuan on January 14, 2026, down 2.02% with a turnover rate of 11.58% and a trading volume of 33,500 hands, resulting in a transaction amount of 187 million yuan [1] Group 1: Financial Performance - For the first three quarters of 2025, Tianyi Medical reported a main revenue of 387 million yuan, an increase of 24.14% year-on-year [3] - The net profit attributable to shareholders reached 20.09 million yuan, up 216.81% year-on-year, while the net profit excluding non-recurring items was 8.41 million yuan, showing a significant increase of 762.11% [3] - In Q3 2025, the company achieved a quarterly main revenue of 160 million yuan, a year-on-year increase of 48.03%, with a quarterly net profit of 10.61 million yuan, up 227.86% year-on-year [3] - The company's debt ratio stands at 42.92%, with an investment loss of 7.25 million yuan and financial expenses of 767,700 yuan, while the gross profit margin is 38.39% [3] Group 2: Capital Flow - On January 14, 2026, the net inflow of main funds was 674,600 yuan, accounting for 0.36% of the total transaction amount, while the net inflow of speculative funds was 28.57 million yuan, making up 15.24% of the total transaction amount [1] - Retail investors experienced a net outflow of 29.24 million yuan, which is 15.6% of the total transaction amount [1] - The financing data indicates that on the same day, the financing buy amounted to 17.95 million yuan, with a financing repayment of 13.82 million yuan, resulting in a net financing increase of 4.13 million yuan [2]
天益医疗（301097）1月14日主力资金净买入67.46万元